Fleishman-Hillard launches managed-markets division

Share this article:

Fleishman-Hillard is moving to cash in on the shift to managed markets with a new healthcare public affairs shop headed by Anne Woodbury, an associate of former Speaker Newt Gingrich, and Sharad Mansukani, one of the architects of the Medicare Modernization Act.
The Omnicom Group company is opening Fleishman-Hillard Health Solutions Navigator, a Washington, D.C., unit offering regulatory and policy communications, reimbursement consulting and media and government relations services including public opinion research, grassroots and coalition development, corporate and cause partnerships, issue
advertising and large-scale public education programs.  
Mansukani was a senior advisor and medical officer at the Center for Medicare and Medicaid Services, and served on the Bush Administration's Medicare Modernization Executive Committee. His focus at CMS was on prescription drug benefits, managed care enhancements and disease-management efforts, along with improving collaboration between CMS, the FDA and the NIH.
Woodbury, a longtime Gingrich aide, was most recently chief health advocate for the former House speaker's Center for Health Transformation.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...